Company Description
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific.
The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases.
It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.
The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports.
In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors.
The company was founded in 2006 and is headquartered in Rostock, Germany.
| Country | Germany |
| Founded | 2006 |
| IPO Date | Nov 7, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 384 |
| CEO | Ms. Kim Stratton |
Contact Details
Address: Am Strande 7 Rostock, 2M 18055 Germany | |
| Phone | 49 30 2130 00325 |
| Website | centogene.com |
Stock Details
| Ticker Symbol | CNTG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $14.00 |
| CIK Code | 0001757097 |
| CUSIP Number | N1976T109 |
| ISIN Number | NL0014040206 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kim Stratton | Chief Executive Officer and Member of Management Board |
| Jose Miguel Coego Rios | Chief Financial Officer, Legal and IT and Member of Management Board |
| Dr. Peter Bauer M.D. | Chief Medical and Genomic Officer and Member of Management Board |
| Dr. Andrin Oswald M.D., Ph.D. | Advisor |
| Ian Rentsch | Chief Commercial Officer and GM of Pharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| May 31, 2024 | 6-K | Report of foreign issuer |
| May 29, 2024 | 6-K | Report of foreign issuer |
| May 17, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| May 15, 2024 | 20-F | Annual and transition report of foreign private issuers |
| May 15, 2024 | 6-K | Report of foreign issuer |
| May 15, 2024 | 6-K | Report of foreign issuer |
| May 14, 2024 | 6-K | Report of foreign issuer |
| May 10, 2024 | 6-K | Report of foreign issuer |
| May 1, 2024 | NT 20-F | Notification of inability to timely file Form 20-F |